2016 Annual Meeting Featured Guests and Speakers

0414-annual-meeting-on-Womens-cancer

2016 Annual Meeting Archive > 2016 Featured Guests and Speakers

Presidential Invited Lectureship: Andrew Futreal, PhD
ABOG Lecturer: Mary-Claire King, PhD
Farr Nezhat Surgical Innovation Session: Olle Ljungqvist, MD, PhD
SGO Presidential Address: Robert L. Coleman, MD

Presidential Invited Lectureship: Andrew Futreal, PhD

Saturday, March 19, 2016
9:15 a.m. – 9:55 a.m.

Andrew Futreal, PhD

Andrew Futreal, PhD

Andrew Futreal, PhD, aims to accelerate the translation of genomic technologies into therapeutic applications. His chief scientific accomplishments include the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes, leading a pioneering effort in large-scale systematic cancer genomics leading to the identification of the BRAF mutations in melanoma, ERBB2 mutations in non-small cell lung cancer and multiple new cancer genes in renal cell carcinoma. Dr. Futreal is a professor in the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. Dr. Futreal applies his knowledge of cancer genomics to improve both short-term and long-term patient outcomes extending to cancer survivorship. He is a platform leader for genomics and informatics for the Moon Shots initiative at MD Anderson. He has published over 182 papers in peer-reviewed journals and received the NIH Public Service Award in 1995 for discovering the BRCA1 gene involved in subsets of breast and ovarian cancer.

ABOG Lecturer: Mary-Claire King, PhD

Sunday, March 20, 2016
2:15 p.m. – 2:55 p.m.

Mary_Claire_King

Mary-Claire King, PhD

Mary-Claire King, PhD, is known worldwide for her major accomplishments in human genetics research. Some of her most noteworthy achievements include identifying the BRCA1 gene responsible for inherited susceptibility to breast cancer, demonstrating that the genomes of humans and chimpanzees are 99% genetically identical, and pioneering the application of genomic sequencing methods in forensics to identify victims of human rights abuse. Her discovery of BRCA1 revolutionized the study of numerous other common inherited diseases. Dr. King is the American Cancer Society Research Professor of Genetics and Medicine at the University of Washington in Seattle. A past president of the American Society of Human Genetics, she has held national and international research and advisory positions with numerous organizations, including the National Commission on Breast Cancer of the President’s Cancer Panel, the advisory board of the NIH Office of Research on Women’s Health, and the Board of Scientific Counselors of NCI. Dr. King is the recipient of the 2014 SGO Foundation for Gynecologic Oncology’s Innovation Award for her significant contributions to the understanding of and approaches to the prevention, diagnosis or treatment of gynecologic cancers.

Farr Nezhat Surgical Innovation Session: Olle Ljungqvist, MD, PhD

Monday, March 21, 2016
9:19 a.m. – 9:49 a.m.

Olle Ljungqvist, MD, PhD

Olle Ljungqvist, MD, PhD

Olle Ljungqvist MD, PhD, is an expert in the field of surgical nutrition, metabolism and perioperative care. He proposed the use of preoperative carbohydrates instead of overnight fasting for elective surgery, which is now recommended in international and national fasting guidelines. He has also been active in research in surgical stress, metabolism and nutrition and outcomes focusing on ERAS, publishing more than 200 original contributions and reviews. Dr. Ljungqvist received his medical degree and obtained his PhD on glucose metabolism in hemorrhage at the Karolinska Institutet in Sweden. He has served as Chair of the European Society for Clinical Nutrition (ESPEN), the International Association for Surgical Metabolism and Nutrition (IASMEN) as part of the International Surgical Society and co-founded the Enhanced Recovery After Surgery (ERAS) Society in 2010.

SGO Presidential Address: Robert L. Coleman, MD

“Improving the Design and Choice of Clinical Trials”
Sunday, March 20, 2016
9:05 a.m. – 9:45 a.m.

Robert L. Coleman, MD

Robert L. Coleman, MD

Robert L. Coleman, MD, is the 47th President of the Society of Gynecologic Oncology (SGO). He has been instrumental in representing SGO in conversations with the FDA on rethinking trial designs to allow for continued drug development in the ovarian cancer space. Dr. Coleman currently is a Professor in the Department of Gynecologic Oncology and Reproductive Medicine and Vice Chair of Clinical Research, and Ann Rife Cox Chair in Gynecology and Deputy Chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. He is MD Anderson’s NRG Oncology Principal Investigator (PI) and is PI or Co-PI for several NRG Oncology prospective clinical trials. In addition to his leadership position within the SGO, Dr. Coleman is an active member of many national organizations, including the American College of Surgeons, American Association for Cancer Research and the American Society of Clinical Oncology.